PfizerPFE
About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Employees: 81,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
44% more first-time investments, than exits
New positions opened: 347 | Existing positions closed: 241
3% more funds holding in top 10
Funds holding in top 10: 40 [Q3] → 41 (+1) [Q4]
2% more funds holding
Funds holding: 2,873 [Q3] → 2,921 (+48) [Q4]
1.21% more ownership
Funds ownership: 64.68% [Q3] → 65.89% (+1.21%) [Q4]
6% less capital invested
Capital invested by funds: $106B [Q3] → $99.6B (-$6.33B) [Q4]
15% less call options, than puts
Call options by funds: $3.27B | Put options by funds: $3.87B
36% less repeat investments, than reductions
Existing positions increased: 919 | Existing positions reduced: 1,445
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
UBS Trung Huynh 13% 1-year accuracy 1 / 8 met price target | 8%upside $24 | Neutral Maintained | 8 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 13%upside $25 | Neutral Downgraded | 8 Apr 2025 |
UBS Colin Bristow 25% 1-year accuracy 3 / 12 met price target | 26%upside $28 | Neutral Maintained | 5 Feb 2025 |
Citigroup Andrew Baum 20% 1-year accuracy 1 / 5 met price target | 31%upside $29 | Neutral Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 109 articles about PFE published over the past 30 days
